Skip to main content
PharmaGraphX
PharmaGraphX
Log inGet Started

Important Disclaimer

PharmaGraphX is a research and educational tool only. It is NOT intended for clinical decision-making, patient care, or medical advice. All drug information, calculations, interactions, and recommendations are for educational and research purposes only. Always consult qualified healthcare professionals, official drug labeling (FDA, TGA, EMA), and institutional guidelines before making any clinical decisions. The developers assume no liability for any decisions made based on information provided by this platform.

© 2026 PharmaGraphX. All rights reserved.

|

For research and educational purposes only. Not medical advice.

Help
  • Navigate between workspaces using the left sidebar.
  • Use the main chat to ask any pharmacology question.
  • Press G then H to quickly navigate home.
Navigation
HomeG H
PK/PD StudioG P
Interaction HubG A
Digital TwinG T
Molecular LabG M

Press Esc to close

  1. Home
  2. /Database
  3. /Vortioxetine

Vortioxetine

Trintellix

Antidepressant • Multimodal serotonin modulator

Premium
BleedingSerotoninergic

Half-life

66 hours

Protein Binding

Metabolized By

CYP2D6, CYP3A4

External

Drugs.com

Mechanism of Action

SERT inhibitor + 5-HT1A agonist + 5-HT1B partial agonist + 5-HT3/5-HT7 antagonist

Indications(5)

Major Depressive DisorderFronto-temporal DementiaFronto-temporal Lobar DementiaFrontotemporal DegenerationFrontotemporal Dementia (FTD)

Classification

Drug Class

Antidepressant

Subclass

Multimodal serotonin modulator

Brand Names

Trintellix

Key Properties

Half-life

66 hours

Time for plasma concentration to decrease by 50%

Protein Binding

—

Fraction bound to plasma proteins

Therapeutic Index

Wide

Margin between therapeutic and toxic doses

Not a substitute for clinical judgement
Vortioxetine Drug Profile | PharmaGraphX